# Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

> **NCT07635342** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 182 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Pyrotinib Maleate
- **DRUG:** Trastuzumab (H, 8mg/kg
- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel for Injection Albumin Bound

## Key facts

- **NCT ID:** NCT07635342
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07635342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07635342, "Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07635342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*